Global health authorities are closely tracking a sudden resurgence of the BA.3.2 COVID-19 lineage. Dubbed the “Cicada” variant, the highly mutated strain is currently driving up to 30% of newly sequenced cases across Northern Europe and spreading rapidly through U.S. wastewater. Against this backdrop of international spread, Taiwan intercepted its first imported case of the virus this week.
A 10-year-old Singaporean girl tested positive upon arriving at Taiwan Taoyuan International Airport on March 14. She registered a 38.5-degree Celsius fever and was immediately isolated until her departure on March 20. The strict quarantine prevented any community transmission, according to a detailed report released on Tuesday by the region’s Centers for Disease Control.
Why they call it the ‘Cicada’ variant
The nickname comes from the virus’s unusual timeline. Scientists first discovered the strain in South Africa in November 2024. It vanished from genomic sequencing radars for nearly a year. Then it suddenly re-emerged and began spreading globally late last year. The World Health Organization officially added BA.3.2 to its “Variants Under Monitoring” list in December 2025.
A heavily mutated spike protein
BA.3.2 descends from the broader Omicron family. But it looks drastically different. The virus carries roughly 70 to 75 mutations on its spike protein compared to older dominant strains like JN.1.
Those specific genetic shifts allow the virus to partially slip past immune defenses built up by older vaccines and prior infections.
Tracking data shows the variant has now reached at least 23 countries. The U.S. CDC recently detected BA.3.2 in wastewater samples spanning 25 different states. Northern European nations like Denmark, Germany, and the Netherlands are seeing the highest concentrations right now.
Current symptoms and severity
The high mutation count sounds alarming. Infectious disease experts stress there is no current evidence indicating BA.3.2 causes more severe illness. Symptoms mirror earlier COVID-19 infections. Updated booster shots are still expected to provide strong defense against severe disease and hospitalization.